Non Small Cell Lung Cancer (NSCLC)

Stage III Met - IV 2nd Line

Failed Therapy

ALK +

VAR0098
Phase I First-in-Human
Dose-Escalation/Safety/Tolerability/Pharmacokinetics of X-396 in Solid Tumors
PI: Wakelee Xcovery

Metastatic Brain

EGFR/HER2
Mutation, Untreated CNS Mets

LUN0082
Phase III Anti-Tumor Activity of Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer
PI: Wakelee Xcovery

Failed EGF/Resistant to TK1 inhibitors

TK1
1st/2nd Generation

TK1
1st/3rd Generation

LUN0083
Phase II/II
AC0010MA Previously Treated EGFRmut & Acquired T790M Mutation Non-Small Cell Lung Cancer
PI: Wakelee AECA Bioscience

LUN0095
Phase I
AZD9291 & Necitumumab in EGFR-Mutant NSCLC After Progression on Previous EGFR TKI
PI: Padda Pending

LUN0090
Phase I
Afatinib&Necitumumab in EGFR Mutation+ NSCLC w/ 1st / 3rd Gen EGFR TKIs Acquired Resistance
PI: Padda Pending

LUN0084
Phase II
RRx-001 in Small NSCLC Prior to Re-administration of Platinum Based Doublet Regimens
PI: Padda EpicentRx, Inc

Failed Platinum Chemo or EGF/ALK/ROS1 Inhibitor

LUN0078
Screening for Tumor Antigen Expression Profiling & HLA Typing in Solid & Hematological Malignancies
PI: Neal AdaptImmune Ltd

Open for Enrollment

Link

Trial Posting

Immunotherapy

Pending

Extension Study

Observational Study

Enrollment on Hold

NY-ESO-1/LAGE-1a

MAGE-A10

LUN0080
I/II MAGE-A10c796T in Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
PI: Neal Pending